NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$2.27-14.66%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put NRXP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens weak on capital allocation, earnings delivery, market reaction to earnings.
View ManagementThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 48% in its worst 12-month stretch.
View RiskNRXP depends on advancing preservative-free ketamine toward FDA approval and commercialization. The company remains unprofitable, with weak recent financial performance and no earnings history here. Its shares trade at 30× sales, versus 10× for peers. The price is roughly in line with forecast growth, despite that valuation gap. Our model puts the next-quarter miss probability near 56%. Its latest surprise was a 62% miss, and management has been unsteady. Peer multiples imply a price about 72% below where it trades. Our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-30. NRXP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering NRXP (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NRXP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NRXP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put NRXP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance FDA approval and commercialization of preservative-free ketamine
ANDA amendment supports FDA approval process for ketamine.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance clinical development and regulatory approval of NRX-100 and NRX-101
Advancing ketamine pipeline supports clinical development objectives.
Advances: Increase revenue through public offerings
Closing the offering confirms capital raised, while dilution tempers the benefit.
Advances: Increase revenue through public offerings
The $20 million offering supports funding but dilutes existing shareholders.
Threatens: Advance clinical development and regulatory approval of NRX-100 and NRX-101
The bearish thesis cites program failures and uncertain depression-market prospects.
Advances: Advance FDA approval and commercialization of preservative-free ketamine
Targeted KETAFREE approval and million-unit batches signal launch readiness, though remain forward-looking.